HCQ group (n = 92) | Corticosteroid group (n = 92) | p value | |
---|---|---|---|
Age (years) | 37.0 ± 10.0 | 37.2 ± 12.6 | 0.91 |
Sex (male/female) | 46/46 | 46/46 | 1.00 |
MAP (mmHg) | 90.6 ± 9.3 | 90.5 ± 9.2 | 0.96 |
Scr (μmol/L) | 119.8 ± 37.7 | 127.6 ± 53.8 | 0.26 |
Baseline eGFR (ml/min/1.73 m2) | 56.8 ± 20.4 | 55.2 ± 22.9 | 0.61 |
Baseline UTP (g/d) | 1.7 (1.2, 2.3) | 1.8 (1.3, 2.5) | 0.96 |
Oxford classification* | |||
M 0/1 | 40/48 | 50/38 | 0.13 |
E 0/1 | 58/30 | 48/40 | 0.12 |
S 0/1 | 24/64 | 27/61 | 0.62 |
T 0/1/2 | 55/26/7 | 51/23/14 | 0.26 |
C 0/1/2 | 28/50/10 | 22/55/11 | 0.61 |
RAASi therapy (% of patients) | 98.9 | 100 | 0.27 |
ACEI alone | 38.0 | 48.9 | |
ARB alone | 46.7 | 42.4 | |
ACEI plus ARB | 14.1 | 8.7 | |
Immunosuppressive therapy (% of patients) | 0 | 42.4 | |
Cyclophosphamide | 32.6 | ||
Mycophenolate mofetil | 5.4 | ||
Calcineurin inhibitors | 2.2 | ||
Leflunomide | 1.1 | ||
Tripterygium glycosides | 1.1 | ||
Aldosterone antagonist therapy (% of patients) | 10.9 | 2.2 | 0.02 |
Traditional Chinese medicine (% of patients) | 2.2 | 5.4 | 0.44 |